» Articles » PMID: 27515547

Clinicopathological Features of Myeloid Sarcoma: Report of 39 Cases and Literature Review

Overview
Specialty Pathology
Date 2016 Aug 13
PMID 27515547
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the clinicopathological features of myeloid sarcoma (MS).

Methods: We retrospectively analyzed the clinicopathological features of patients with MS and reviewed the relevant literature.

Results: There were 39 patients (20 male and 19 female, with a ratio of 1.1:1) aged 2-62 years (median: 33 years; mean: 33.4 years), with 53.9% patients in the 21-50 years age group. The clinical manifestations varied and were dependent on the lesion location. Immunohistochemistry and special staining showed that the positive rates for myeloperoxidase, CD43, CD34, CD117, CD68, Lysozyme, CD99, and naphthol AS-D chloroacetate esterase were 92.1% (35/38), 91.3% (21/23), 44.8% (13/29), 42.3% (11/26), 61.1% (11/18), 100.0% (5/5), 78.6% (11/14), and 55.6% (10/18), respectively. Histologically, the cells were predominantly arranged diffusely, and the solitary infiltrating cells may show an acinus-like arrangement, while some cells were arranged in linear or "Indian file" pattern. Obvious small nucleoli were seen in most cases. The nuclei were predominantly round or oval, although eccentric, kidney-shaped, and lobulated nuclei were also observed. A varied number of eosinophilic granulocytes were found in most cases. The "starry sky" appearance was observed in a few patients. Among 18 patients, the survival rate was 38.9% and the median survival time was 28 months. MS occurred following allogeneic stem cell transplantation in 5 cases. There were 14 de-novo (45.2%,14/31) and 17 secondary MS (54.8%, 17/31). As for de-novo MS, female rates was higher (64.3% vs. 29.4%), older average years (41.4 vs. 31.1 years), older middle years (47.5 vs.32 years).

Conclusions: The combined application of morphology, immunohistochemistry, and special staining may facilitate the diagnosis of this malignancy. Surgery plus chemotherapy remains the most common treatment for MS. The prognosis of MS was bad.

Citing Articles

Diagnostic Approaches in Myeloid Sarcoma.

Patkowska E, Krzywdzinska A, Solarska I, Wojtas M, Prochorec-Sobieszek M Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996833 PMC: 11853749. DOI: 10.3390/cimb47020111.


Pulmonary Manifestations in Patients With Hematologic Malignancies: In Pursuit of an Accurate Diagnosis.

Alvarez-Payares J, Ribero Vargas D, Suarez E, Barrera-Correa D, Velez Aguirre J, Hernandez-Rodriguez J Cureus. 2025; 17(1):e77418.

PMID: 39949462 PMC: 11822728. DOI: 10.7759/cureus.77418.


Lymph node myeloid sarcoma with TP53‑associated myelodysplastic syndrome: A case report.

Mao M, Deng S Oncol Lett. 2024; 28(1):324.

PMID: 38807682 PMC: 11130743. DOI: 10.3892/ol.2024.14458.


Non-Mass-Forming Myeloid Sarcoma of the Colon Presenting With Diarrhea.

Elsharawi I, Williams S, Stueck A ACG Case Rep J. 2023; 10(12):e01213.

PMID: 38089536 PMC: 10713148. DOI: 10.14309/crj.0000000000001213.


Acute Myeloid Leukemia Masquerading As Testicular Mass: A Case Report.

Ravikumar D, Ambalavana K, Elumalai S, Vijayaraghavan N, Ramesh N Cureus. 2023; 15(10):e47715.

PMID: 38022116 PMC: 10675843. DOI: 10.7759/cureus.47715.